US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk

What happened

A US judge rejected Novo Nordisk's request to block Eli Lilly's weight-loss drug advertisements while their case continues. Judge Zahid Quraishi ruled the claimed harm was too inadequate to justify an injunction, meaning a court order to stop the ads.

Confirmed

Global impact / market context

The ruling lets Eli Lilly keep running ads that compare its drugs with Novo Nordisk's, which may help it win US prescriptions. Novo Nordisk is trying to regain market share, so continued advertising pressure could affect its revenue and costs.

Analyst inference

Weight-loss drugs are major businesses, and the US is one of few countries allowing direct-to-consumer prescription medicine ads. That makes advertising a real competitive tool, so legal fights over ad claims can influence investor views on both companies.

Analyst inference

What to watch

1. The case continues after the judge's rejection of a preliminary injunction, which would have paused Eli Lilly's ads during litigation. Confirmed
2. Novo Nordisk could pursue its false advertising and unfair competition claims further, seeking another way to limit Eli Lilly's comparative ad claims. Proposed
3. Watch US prescription trends and ad spending for Wegovy, Ozempic, Zepbound and Mounjaro, since market share shifts can affect revenue. Analyst inference

Evidence

• Original source link unavailable